What is the efficacy of thrombopoietin receptor agonists in the treatment of immune thrombocytopenic purpura (ITP)?

Updated: Apr 22, 2018
  • Author: Craig M Kessler, MD, MACP; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
  • Print
Answer

The limited clinical experiences with these agents are promising. However, the ultimate efficacy and safety of these new agents will not be fully evaluable until data on larger numbers of patients become available.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!